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Clinical trials using anti-vascular endothelial growth factor /(VEGF) molecules induce a modest improvement in
overall survival, measurable in weeks to just a few months, and tumors respond differently to these agents. In this
review article, we have exposed some tumor characteristics and processes that may impair the effectiveness of
anti-angiogenic approaches, including genotypic changes on endothelial cells, the vascular normalization
phenomenon, and the vasculogenic mimicry. The usage of anti-angiogenic molecules leads to hypoxic tumor
microenvironment which enhances tumor invasiveness. The role of tumor-infiltrating cells, including tumor
associated macrophages and fibroblasts (TAMs and TAFs) in the therapeutic response to anti-angiogenic settings
was also highlighted. Finally, among the new therapeutic approaches to target tumor vasculature, anti-PD-1 or anti-
PD-L1 therapy sensitizing and prolonging the efficacy of anti-angiogenic therapy, have been discussed.
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Anti-angiogenesis therapy started in 2004 (Table 1), with the
approval by Food and Drug Administration (FDA) of the first
anti-angiogenic drug, bevacizumab (Avastin), a humanized mono-
clonal antibody anti- VEGF-A, approved for the treatment of
previously untreated metastatic colorectal cancer in combination with
chemotherapy [1]. Bevacizumab can be given safely for long periods,
with manageable toxicity when added to chemotherapy, even if it
induces severe side effects, including lethal hemoptysis and intestinal
perforations [2,3]. The small molecule tyrosine kinase inhibitors
(TKIs), including sunitinib, sorafenib, and pazopanib, are another
class of anti-angiogenic drugs, able to interfere with vascular
endothelial growth factor receptors-1 and -2 (VEGFR-1 and
VEGFR-2), platelet derived growth factor receptor (PDGFR),
fibroblast growth factor receptors (FGFRs), and Tie signaling
(Table 2) [4]. VEGFR-trap protein aflibercept, formed by fusion of
the VEGF binding domain of VEGFR-1 and VEGFR-2 has been
approved for metastatic colorectal cancer [5].
Therapeutic inhibition of angiogenesis has been associated with
increased local invasiveness and distant metastasis, as shown for the
first time in 2009 [6,7]. Sunitinib and the anti VEGFR-2 antibody
DC101 stimulated the invasive behavior of tumor cells despite their
inhibition of tumor growth [6,7]. Increased invasiveness might resultfrom enhanced expression of angiogenic cytokines induced by the
treatment, including VEGF and placental growth factor (PlGF), or
recruitment of endothelial progenitor cells (EPCs), that promote the
formation of a pre-metastatic niche [8]. Inherent or acquired
resistance to anti-VEGF molecules can occur leading to a lack of
response and to disease recurrence, although discontinuation of the
therapy is the principal factor limiting the effectiveness of
anti-angiogenic therapies [9]. Moreover, anti-angiogenic treatment
reduces drugs delivery to tumors, restricting their efficacy [10].
Tumors use multiple pathways for recruiting vessels and blocking
VEGF alone has incomplete effects on tumor vasculature, and tumors
Table 1. Approved anti-angiogenic agents for cancer and their indications
Monoclonal antibodies Bevacizumab - metastatic colorectal
- cancer
- non-small cell lung cancer
- glioblastoma multiforme
- renal cell carcinoma
- epithelial ovarian cancer
- fallopian tube cancer
- primary peritoneal cancer
- cervical cancer
Ramucirumab - metastatic colorectal cancer
- non-small cell lung cancer
- gastric or gastroesophageal
junction adenocarcinoma
Tyrosine kinase inhibitors (See Table 2)
Fusion protein Ziv-aflibercept - metastatic colorectal cancer
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express several angiogenic factors including VEGF, transforming
growth factor beta (TGFβ), PlGF and platelet derived growth factor
(PDGF) [11]. Other factors involved in compensatory angiogenic
signaling are FGF-2, hepatocyte growth factor/scatter factor (HGF/
SF), angiopoietins (Angs), and interleukin-8 (IL-8) [12–16].Long-Term Anti-Angiogenic Therapy Leads to
Tumor Hypoxia
Tumor hypoxia is a consequence of inadequate oxygen supply caused
by extensive abnormalities in the vascular network, including
elongated and tortuous vessels, aberrant vessel diameters, and vessel
wall abnormalities (i.e., incomplete endothelial lining, interruptedTable 2. Anti-angiogenic tyrosine kinase inhibitors in clinical development
Agent Target










Pazopanib (GW786034; Votrient) • VEGFR-1, -2, -3
• PDGFR
• KIT




Axitinib (AG013736) • VEGFR-1, -2, -3
• PDGFR-β
• KIT
Cediranib (AZD2171; Recentin) • VEGFR-1, -2, -3
• PDGFR-β
• KIT
Vatalanib (PTK787; ZK222584) • VEGFR-1, -2, -3
• PDGFR-β
• KIT




CSF-1R colony stimulating factor-1 receptor, EGFR epidermal growth factor receptor, FLT3 fms-rela
receptor, VEGFR vascular endothelial growth factor receptor, RET, rearranged during treatment, RAbasement membrane, and lack of pericytes and contractile vessel wall
components) [17].
Anti-angiogenesis is responsible for a temporary decrease in tumor
hypoxia, which parallels the maturation of the vasculature. VEGF
inhibition could temporarily normalize the function of
tumor-associated vasculature, decreasing vascular permeability in
conjunction with restoration of sustained pressure gradients, thereby
enhancing systemic delivery of oxygen or perfusion of cytotoxic
agents to intratumoral sites [18]. In combination with chemotherapy,
such vascular normalization strategies can improve drug delivery and
cancer growth control [19].
The window of vascular normalization occurs transiently during
the first days of treatment. When the tumor blood vessels lose their
maturation [20] hypoxia re-increases and prolonged VEGF inhibition
further increases local hypoxia [21], which in turn induces systemic
secretion of other angiogenic cytokines [7,22–24]. Hypoxia within
tumor increases during treatment with an anti-angiogenic agent,
inducing pH drop and consequent acidosis [19]. Hypoxic conditions
could also select more malignant cells, i.e. those able to grow in
hypoxic conditions [25]. Moreover, hypoxia, produces a pressure
mechanism that selects tumor cells with increased aggressiveness and
lower sensitivity to anti-angiogenic therapy [23]. In fact, blood supply
to the tumor remains heterogeneous and hypoxia increases while the
permeability of tumor blood vessels is reduced, favoring disappointing
results of clinical trials where anti-angiogenic therapies have been
combined with systemic delivery of chemotherapeutic agents.
Hypoxia promotes the differentiation of tumor infiltrating myeloid
cells to M2-pro-angiogenic tumor associated macrophages (TAMs)
[26], and neovascularization through the mobilization of boneClinical activity and/or study
Kidney, breast, prostate, lung, liver, ovarian, colorectal,
thyroid, head and neck, gastric, bladder, cervical and pancreatic cancer,
GIST, melanoma, glioblastoma, myeloma, lymphoma
Kidney, liver, breast, prostate, lung, ovarian, colorectal,
thyroid, head and neck, gastric and pancreatic cancer, GIST,
melanoma, glioblastoma, lymphoma, leukemia
Kidney, breast, lung, cervical, liver, thyroid, prostate and
colorectal cancer, melanoma, glioblastoma
Lung, kidney, thyroid, head and neck, prostate, ovarian, breast and
colorectal cancer, glioma, neuroblastoma
Kidney, lung, thyroid, pancreatic, colorectal and breast cancer, melanoma
Kidney, breast, lung, liver, ovarian, head and neck, prostate and colorectal
cancer, GIST, glioblastoma, melanoma
Prostate, colorectal, kidney and pancreatic cancer, melanoma, lymphoma, leukemia
Lung, thyroid, gallbladder, breast and colorectal cancer, GIST
ted tyrosine kinase 3, GIST gastro-intestinal stromal tumor, PDGFR platelet-derived growth factor
F, rapid accelerated fibrosarcoma
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promotes genetic instability in tumor endothelial cells [28], and
induces the selection of more invasive metastatic clones of the cancer
cells that are resistant to anti-angiogenic agents [29], through the
production of pro-migratory proteins, such as stromal cell derived
factor 1 alpha (SDF1-α) and HGF/SF and pro-invasive extracellular
matrix proteins [30,31], which may stimulate mobilization and
recruitment of EPCs and other bone marrow-derived cells [32,33].
Genotype Alterations
The cells of the tumor vasculature are more genetically stable than
tumor cells, express specific antigens [34] and are more accessible for
therapeutic molecules and immune cells, even if gene and
chromosomal abnormalities have been documented in subpopula-
tions of tumor endothelial cells, including aneuploidy, abnormal
multiple chromosomes, and aberrant chromosomse [35].
Colorectal cancer endothelial cells overexpress specific transcripts
as a result of qualitative differences in gene profiling compared with
endothelial cells of the normal colorectal mucosa [36]. A distinct gene
expression pattern related to extracellular matrix and surface proteins
characteristic of proliferating and migrating endothelial cells has been
demonstrated in glioma and invasive breast carcinoma [37,38].
Tumor endothelial cells isolated from human renal cell carcinoma
are resistant to apoptotic stimuli with enhanced Akt activation and
decreased expression of the tumor suppressor phosphatase and tensin
homolog deleted from chromosome 10 (PTEN) [39]. Cytogenetic
abnormalities are an expression of genetic instability and could
explain the resistance of tumor endothelial cells to chemotherapeutic
agents, including vincristine [39], 5-fluorouracil, adriamycin, and
paclitaxel [40,41].
Cells of the Microenvironment
TAMs have been considered as primary cause of resistance to
anti-VEGF agents [42]. PlGF mediated recruitment of
pro-angiogenic TAMs might be a mechanism for tumor resistance
[43]. Refractoriness to anti-angiogenic therapies in glioblastoma
multiforme patient is associated with higher number of CD68+
TAMs and CD11b+ myeloid cells [44]. Blocking the recruitment of
TAMs may be a mechanism to overcome resistance to anti-angiogenic
therapy. VEGFR-2 inhibition in RIP1-Tag2 pancreatic neuroendo-
crine tumors upregulates Ang-2, enhances infiltration of Tie2Table 3. Events in tumor blood vessels normalizatonexpressing macrophages, and suppresses revascularization and tumor
progression [45].
Tumor associated fibroblasts (TAFs) secrete several angiogenic
growth factors, including epidermal growth factor (EGF), HGF,
insulin-like growth factor, and FGF-2 [46]. TAFs are involved in
resistance to anti-angiogenic therapy. In particular, CAFs generated
PDGF-C, which is a key factor in sustaining angiogenesis and tumor
growth under anti-VEGF treatment [13]. Pericytes can protect
endothelial cells from VEGF withdrawal by activating compensatory
pro-angiogenic pathway in anti-VEGF therapy [47].
Cancer Stem cells (CSCs) generate angiogenic factors to stimulate
tumor angiogenesis, and tumor vasculature, in turn, supports CSC
self-renewal and maintaining [48]. Moreover, CSCs recruit endothe-
lial precursors for revascularization and tumor re-growth [49], and
may be involved in tumor resistance as a consequence of their
capability to produce much higher levels of VEGF in both anoxic and
hypoxic environments than non-CSC population [50].
Bone marrow derived cells (BMDCs) are a major reserve of EPCs,
which play an important role in tumor angiogenesis independent of
VEGF [51]. The immature myeloid cell [52] and EPCs [53] infiltrate
the tumor and mediate the resistance by incorporating themselves
into vessels or by releasing pro-angiogenic growth factors [54].
Tumor Blood Vessels Normalization (Table 3)
Tumor vascular normalization is accompanied by increased pericyte
coverage, while pericyte deficiency could be partly responsible for
vessel abnormalities in tumor blood vessels [55] and partial
dissociation of pericytes contribute to increased tumor vascular
permeability [56]. Pericyte coverage promotes resistance through
direct support or paracrine interactions with endothelial cells and
tumor vessels covered by pericytes are less sensitive to VEGF
blockade [57].
Vascular normalization improves T cell extravasation and promotes
the conversion of pro-angiogenic (M2-like) into angiostatic (M1-like)
TAMs [58]. TAMs usually exhibit M2-like phenotype, secreting
immunosuppressive cytokines, such as IL-10, CCL17 and CCL22
and producing pro-angiogenic and tissue remodeling factors, such as
VEGF, PlGF and matrix metalloproteinase-9 (MMP9) [59]. The
increase of oxygenation in histidine-rich glycoprotein (HRG)-positive
tumors caused by vascular normalization seems to provide a stimulus
for polarizing TAMs away from M2-like type, which could further
Table 4. Mechanisms are involved in anti-angiogenic therapy resistance.
Redundancy in growth factor signaling
Recruitment of bone marrow-derived cells
Stromal cells
Intussusceptive microvascular growth, vasculogenic mimicry, and vessel co-option
Redundancy in growth factor signaling
Increased invasiveness and metastasis
Endothelial heterogeneity
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growth and metastasis [60].
In the case of cerebral tumors, the process of normalization may
induce a re-establishment of the low permeability characteristics of
normal brain microvasculature, preventing the delivery of chemother-
apeutics [61]. In the meantime, vascular normalization induces a drop
in interstitial fluid pressure and reduction in hypoxia, which provide an
improvement of the penetration and activity of cytotoxic drugs [62].
The state of vascular normalization generally is transient and in
this context tumor is more receptive to delivery of chemotherapeutic
drug and immune cell populations [63]. However, there appears to be
a high degree of variation in temporal window of vascular
normalization for various anti-angiogenic agents [64].
Alternative Mechanisms of Formation of Tumor
Vasculature
Other modes of tumor vascularization may be less sensitive to
anti-angiogenic therapies. Intussusceptive microvascular growth
(IMG) (“intussusception, known also as or non-sprouting or splitting
angiogenesis”) is a concept of microvascular growth relevant for many
vascular systems, which constitutes an additional and alternative
mechanism to endothelial sprouting [65]. In IMG, the capillary
network increased its complexity and vascular surface by insertion of a
multitude of transcapillary pillars, a process they called “intussuscep-
tion” (meaning “in-itself” growth) [65]. IMG generates vessels more
rapidly with a less metabolic demand as compared to sprouting
angiogenesis and is a strategy that tumors can use for rapid adaptation
to milieu changes [65]. IMG has been observed in several human
tumors, including melanoma, colon, mammary carcinomas, B-cell
non-Hodgkin's lymphoma and glioblastoma [65].
In the course of the so called “vasculogenic mimicry,” blood vessels
are generated without the participation of endothelial cells through a
differentiation of tumor cells into endothelial-like cells, and
independent of classical angiogenic factors, including FGF-2 and
VEGF [66]. Vasculogenic mimicry has been observed in different
human malignant tumors, including breast, melanoma, bladder,
kidney, glioblastoma, prostate, ovarian, lung, sarcomas, cell renal cell
carcinoma and astrocytoma [67]. An increase in vasculogenic mimicry
has been demonstrated after anti-angiogenic treatment with
Bevacizumab [68].
Vascular co-option occurs in site of metastases or in densely
vascularized organs. Tumor cells co-opt and grow as cuffs around
adjacent vessels [69]. The prevalence of vessel co-option in in liver
metastasis of breast and colorectal cancer [70] may explain why
anti-angiogenic therapies are poorly effective in these pathological
conditions. Vessel co-option could explain the onset of resistance to
anti-angiogenic regimens in glioblastoma multiforme, hepatocellular
carcinoma, and in metastasis to lung [71–73]. Moreover, anti-VEGF
antibody treatment is responsible of an increased vessel co-option [73].
Simultaneous inhibition of angiogenesis and vessel co-option may
represent a further improvement of the therapeutic approach [70].
Therapeutic Vaccines Promoting Immune
Targeting of Tumor Vascular Cells
The programmed death protein 1 (PD-1), its ligand the programmed
death ligand 1 (PD-L1) and the cytotoxic T-lymphocyte-associated
antigen 4 (CTLA-4) are negative regulators of T-cell immune
function. Direct stimulation of the immune system with immune
check-point inhibitors, such as antibody against PD-1/PD-L1 and
CTLA-4 has been reported in multiple cancers. Antibodies againstCTLA-4 and PD-1/PDL-1 have proven efficacy in different tumor
types and five drugs of this class have been approved by the FDA [74].
The production of angiogenic molecules by tumor cells inhibits the
expression of adhesion molecules involved in leukocyte interactions
with blood vessels, including intercellular cell adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin
and CD34, preventing adhesion and extravasation of effector T cells
into the tumor [63]. The anergic phenotype of tumor endothelial cells
can be reversed by anti-angiogenic therapy, which upregulates the
expression of endothelial adhesion molecules in the tumor vasculature
[75]. Abrogating VEGF signaling thus looks like an immunothera-
peutic strategy.
Vaccination based on tumor blood vessel associated antigens
(TBVA) normalizes the vasculature, induces T cell effector response,
and inhibits tumor growth in murine models [76]. Two major types
of vaccines are being developed, namely vaccines against defined
angiogenesis-associated antigens, and whole endothelial cell vaccines,
expressing numerous angiogenic antigens, using whole endothelial
cells or isolated proteins from endothelial cell membranes [77].
Moreover, VEGF decreased in patients with metastatic melanoma
responding to sequential anti-CTLA-4 and anti-PD-1 therapy, but
increased in non-responders, indicating a mechanism of therapeutic
resistance [78].
A cl in ica l s tudy of a combinat ion therapy us ing
antibody-anti-CTLA-4 with bevacizumab reported efficacy in
patients with metastatic melanoma with a median overall survival
of more than 2 years [79].
Anti-PD-1 or anti-PD-L1 therapy sensitized and prolonged the
efficacy of anti-angiogenic therapy and improved anti-PD-L1
favoring vascular changes such as vascular normalization that facilitate
enhanced cytotoxic T cell infiltration [80]. Moreover, CD4+ T cell
activation by immune-checkpoint blockade increased vessel normal-
ization, as indicated by increased pericyte coverage, improved tumor
vessel perfusion and reduced vascular permeability [81].Concluding Remarks and Perspectives
Different mechanisms are involved in anti-angiogenic therapy
resistance, in both pre-clinical and clinical setting (Table 4). The
fact that tumors may grow without angiogenesis, through alternative
mode of vasculature neo-formation, make them less likely to respond
to anti-angiogenic drugs.
Alternative therapeutic strategies may be used to overcome
resistance to anti-angiogenic therapy, including the association of
multiple anti-angiogenic compounds or a combination of
anti-angiogenic drugs with other treatment regimens. Effectiveness
of the combination therapy should be monitored during disease
progression with the aim of optimize the therapy and counteract the
development of further resistance.
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